Were Christy Jones’s Beta Bionics (BBNX) share sales discretionary or pre‑planned?

The reported sale of 1,998 Beta Bionics shares by Christy Jones was made under a Rule 10b5‑1 Plan adopted on February 19, 2026. Such plans are pre‑arranged trading programs designed to schedule transactions in advance under specified conditions.

Beta Bionics (BBNX) director logs stock grant and 1,998-share sale

Filing Impact

(Neutral)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Beta Bionics, Inc. director Christy Jones reported both a stock award and a small share sale. On May 21, 2026, Jones received a grant of 16,965 shares of common stock as a restricted stock unit award under the company’s 2025 Equity Incentive Plan, at no cash cost.

On the same date, Jones sold 1,998 common shares at $9.95 per share in an open‑market transaction. According to the filing, this sale was made pursuant to a Rule 10b5‑1 trading plan adopted on February 19, 2026, and Jones held 13,246 common shares directly after the sale.

Insider Trade Summary 10b5-1

Net Seller: 1,998 shares ($19,880)

Net Sell 2 txns

Insider Jones Christy

Role null

Sold 1,998 shs ($20K)

Type	Security	Shares	Price	Value
Sale	Common Stock	1,998	$9.95	$20K
Grant/Award	Common Stock	16,965	$0.00	--

Holdings After Transaction: Common Stock — 13,246 shares (Direct, null)

Footnotes (1)

Represents shares sold pursuant to a Rule 10b5-1 Plan adopted on February 19, 2026. Represents restricted stock unit award granted under the Issuer's 2025 Equity Incentive Plan.

Key Figures

RSU grant: 16,965 shares Shares sold: 1,998 shares Sale price: $9.95 per share +2 more

5 metrics

RSU grant 16,965 shares Restricted stock unit award on May 21, 2026

Shares sold 1,998 shares Open-market sale on May 21, 2026

Sale price $9.95 per share Price for 1,998 common shares sold

Holdings after sale 13,246 shares Direct common stock position following the sale

10b5-1 plan adoption date February 19, 2026 Date Rule 10b5-1 trading plan was adopted

Key Terms

Rule 10b5-1 Plan, restricted stock unit, Equity Incentive Plan, open-market sale

4 terms

Rule 10b5-1 Plan regulatory

"Represents shares sold pursuant to a Rule 10b5-1 Plan adopted on February 19, 2026."

A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.

restricted stock unit financial

"Represents restricted stock unit award granted under the Issuer's 2025 Equity Incentive Plan."

A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.

Equity Incentive Plan financial

"award granted under the Issuer's 2025 Equity Incentive Plan."

An equity incentive plan is a program that gives employees, executives or directors the right to receive company stock or options to buy stock as part of their pay. Think of it as offering slices of future company profit to motivate people to boost long‑term performance; for investors it matters because it can align employee goals with shareholder value but also increases the number of shares outstanding, which can dilute existing ownership.

open-market sale financial

"Sale in open market or private transaction"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

05/26/2026 - 06:00 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Jones Christy

(Last)

(First)

(Middle)

C/O BETA BIONICS, INC.

11 HUGHES

(Street)

IRVINE

CALIFORNIA

92618

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Beta Bionics, Inc. [ BBNX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/21/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	05/21/2026		S⁽¹⁾		1,998	D	$9.95	13,246	D
Common Stock	05/21/2026		A		16,965⁽²⁾	A	$0	30,211	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Represents shares sold pursuant to a Rule 10b5-1 Plan adopted on February 19, 2026.

2. Represents restricted stock unit award granted under the Issuer's 2025 Equity Incentive Plan.

	/s/ Stephen Feider, Attorney-in-Fact	05/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did Beta Bionics (BBNX) director Christy Jones report?

Christy Jones reported a grant of 16,965 shares of Beta Bionics common stock and a sale of 1,998 shares. Both transactions occurred on May 21, 2026, and involved directly held common stock positions reported on a Form 4 filing.

How many Beta Bionics (BBNX) shares did Christy Jones sell and at what price?

Christy Jones sold 1,998 shares of Beta Bionics common stock at $9.95 per share. The sale was reported as an open‑market transaction and was executed under a pre‑arranged Rule 10b5‑1 trading plan adopted on February 19, 2026.

What stock award did Christy Jones receive from Beta Bionics (BBNX)?

Christy Jones received a restricted stock unit award covering 16,965 shares of Beta Bionics common stock. The award was granted at no cash cost under the company’s 2025 Equity Incentive Plan and was reported as a grant or award acquisition.

How many Beta Bionics (BBNX) shares does Christy Jones hold after these transactions?

After the reported open‑market sale of 1,998 shares, Christy Jones directly held 13,246 shares of Beta Bionics common stock. This post‑transaction holding figure is taken from the Form 4 entry for the sale dated May 21, 2026.

Under which plan was Christy Jones’s Beta Bionics (BBNX) stock grant made?

Christy Jones’s grant of 16,965 shares was issued as a restricted stock unit award under Beta Bionics’ 2025 Equity Incentive Plan. This plan governs equity‑based compensation awards for eligible participants within the company’s established framework.